A clinical-stage biopharmaceutical entity focused on leveraging artificial intelligence to identify and develop new treatments in neuroscience and immuno-oncology. Its approach involves repurposing existing compounds and accelerating drug discovery using computational platforms.
2017
United States
11 - 50 employees
Biotechnology
$1M - 10M in revenue
Not profitable
See all
Carbon emissions
Electricity consumption
Carbon certificate projects
Targets
SDG Impact
Quantified controversy level of a company based on the number of active lawsuits and media sentiment, tracked across 100,000+ proprietary media inputs
Fake Job Title 1
**************
Fake Job Title 2
**************
Disclaimer: The information provided by illuminem ("we", "us") is for general informational purposes only. All information on the pages is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy of any information on the pages. The information on the pages is either provided to us directly by the companies to which the information relates, or by third-party data providers, or derives from publicly available sources. In certain instances the information might be estimations based on limited information publicly available. Your reliance on any information provided on the pages is solely at your own risk. If you believe that any information is incorrect or in breach of your rights, please contact us.